| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
5
5
4
3
5
|
|
Zacks Investment Research
1
(Strong Buy)
|
|
Standard & Poor's
4 / 5 Stars
|
|
TheStreet.com
A-
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Short | % Net | |
|---|---|---|---|
| Cash | 0.79 | 0.0 | 0.79 |
| Stocks | 94.03 | 0.0 | 94.03 |
| Bonds | 0.0 | 0.0 | 0.0 |
| Other | 0.0 | 0.14 | -0.14 |
| Foreign Bonds | 0.0 | 0.0 | 0.0 |
| Foreign Stocks | 5.32 | 0.0 | 5.32 |
| Convertible | 0.0 | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 | 0.0 |
Updated 04.30.2013
Top 10 Holdings
Performance as of 05.31.2013
Portfolio as of 04.30.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Amgen Inc | AMGN | 16.09 | 8.16 |
| Gilead Sciences Inc | GILD | 44.64 | 8.04 |
| Biogen Idec Inc | BIIB | 55.35 | 6.97 |
| Celgene Corporation | CELG | 54.06 | 6.2 |
| Regeneron Pharmaceuticals, Inc. | REGN | 38.0 | 4.48 |
| Vertex Pharmaceuticals | VRTX | 89.33 | 4.31 |
| Alexion Pharmaceuticals, Inc. | ALXN | 1.86 | 3.93 |
| Life Technologies Corp | LIFE | 51.4 | 3.33 |
| Illumina, Inc. | ILMN | 27.5 | 2.74 |
| Biomarin Pharmaceutical, Inc. | BMRN | 21.5 | 2.55 |
